The US Food and Drug Administration (FDA) has granted approval for Bristol Myers Squibb’s (BMS) Opdivo (nivolumab) in combination with Yervoy (ipilimumab) as a first-line treatment for adults with ...

Bristol-Myers Squibb must make the case for its Opdivo cancer immunotherapy to be included on England’s Cancer Drugs Fund in lung cancer, after NICE asked for more information on its ...

Opdivo gained rapid approval in the US after having gained 'Breakthrough Therapy Designation', and was also identified as a promising innovative medicine (PIM) for lung cancer by the UK's drug ...

Replimune Group, Inc.'s RP1 + OPDIVO for advanced melanoma gains FDA Priority Review. PDUFA date: July 22, 2025. Read more on ...

Opdivo (nivolumab) is a prescription drug that’s used to treat certain types of cancer. Opdivo can cause side effects that range from mild to serious. Examples include joint pain, rash ...

Approval of Opdivo plus Yervoy combination was based on results from the Phase III CheckMate-9DW trial, which demonstrated ...

Subcutaneous Opdivo showed comparable effectiveness, safety and tolerability to IV Opdivo in advanced clear cell renal cell ...

The U.S. Food and Drug Administration has approved Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment for ...

The FDA has approved Opdivo plus Yervoy for the first-line treatment of MSI-H/dMMR colorectal cancer, supported by the Phase 3 CheckMate-8HW trial results.

Based on the Phase 3 CheckMate-8HW trial, Opdivo plus Yervoy demonstrated reduction in the risk of disease progression or death by 79% vs. chemotherapy in the first-line setting and by 38% vs.

Bristol Myers BMY reported better-than-expected first-quarter 2025 results. Adjusted earnings per share (EPS) of $1.80 ...